Estadísticas

	Visualizaciones
The decline of BCR-ABL/GUS ratio in CML patients treated upfront with nilotinib shows a rapid descent during the first trimester, and the responses are similar to those achieved with ABL as control	66

Seleccione un intervalo de tiempo:

	Visualizaciones
The decline of BCR-ABL/GUS ratio in CML patients treated upfront with nilotinib shows a rapid descent during the first trimester, and the responses are similar to those achieved with ABL as control	13

Repositorio digital RUNA